Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • In Korea most of cases are squamous

    2020-08-28

    In Korea, most of cases ActinomycinD squamous cell carcinomas (SCC) (ap-proximately 80%) followed by adenocarcinomas (ADC), although an increase in the proportion of ADC was reported (from 8.9% in 1993 to 16.1% in 2009). Unlike a downtrend in ASR-incidence of SCC (from
    14.1 per 100,000 in 1993–7.0 per 100,000 in 2012), ASR-incidence of ADC has remained fairly stable over time (Fig. 2) [1,26]. These could be explained by several factors including duration and quality of screening programmes and changes in cervical cancer risk factors, such as sexual behaviour and HPV exposure.
    3.3.2. HPV prevalence and type distribution
    HPV prevalence in the Republic of Korea, by lesion severity and study.
    Reference Study design HPV detection and targeted HPVs Age
    HPV Prevalence
    range
    Low–grade lesions High–grade lesions Cervical cancer
    (years)
    Any HPV 5 most frequent Any HPV 5 most frequent Any HPV 5 most frequent
    from pathology archives from the
    Department of Pathology of the
    Yonsei University colleague of
    Cohort study among women attending
    Gynecology, Inha University Hospital
    screening in healthcare centres in
    and at the Pundang CHA Hospital
    and Gynecology in Seoul National
    Reference Study design HPV detection and targeted HPVs Age
    HPV Prevalence
    range
    Low–grade lesions High–grade lesions Cervical cancer
    (years)
    Any HPV 5 most frequent Any HPV 5 most frequent Any HPV 5 most frequent
    Obstetrics and Gynecology of the
    KangnamSt Mary’s Hospital, Catholic
    Cohort study among consecutive
    National Cancer Center,
    Cohort study among women visited
    924d Department of Obstetrics and
    Gynecology of Chonnam National
    University Hospital (Gwangju)
    Retrospective cross–sectional study
    National Medical Center (Seoul) and
    Dong–A University Hospital (Busan)
    Case–control (hospital based) study
    (continued on next page) 
    Reference Study design HPV detection and targeted HPVs Age HPV Prevalence
    range
    Low–grade lesions High–grade lesions Cervical cancer
    (years)
    Any HPV 5 most frequent Any HPV 5 most frequent Any HPV 5 most frequent
    Healthcare System Gangnam Center
    for a routine health check–up
    countries, including South Korea
    Retrospective cross–sectional study
    screen in 13 Korean cities
    The samples for HPV testing come from cervical specimens (fresh/fixed biopsies or exfoliated cells).
    (f) Women from the general population, including some with cytological cervical abnormalities. a Only type specific prevalence for Insertions HR HPV.
    b Only cases of cervical adenocarcinoma. c Any HPV prevalence and type specific prevalence for HR HPV. d Type specific prevalence for HR HPV. e Includes 2 cases with squamous cell carcinoma. g Includes carcinoma.
    Table 3
    Burden of cancer in anatomical sites related to HPV, in the Republic of Korea, compared to Eastern Asia.
    Republic of Korea
    Eastern Asia
    N Crude ratea ASRa N Crude ratea ASRa
    Cervix Incidence
    Vulva Mortality
    Incidence
    Penis Mortality
    Incidence
    Oropharynx Mortality Overall 20 0.08 0.05
    “N”: number of cases; “ASR”: Age-standardized rate.
    Age group (years)
    Incidence
    Mortality
    Fig. 1. Age–specific incidence and mortality rates from cervical cancer in the Republic of Korea, in 2015.. Data sources [1] 
    Fig. 2. Trends in cervical cancer incidence in the Republic of Korea, by his-tology. “SCC”: Squamous cell carcinoma; “ADC”: Adenocarcinoma; “ASR”: Age-standardized rate.. Data sources: Adapted from [1,26]
    Population-based cancer survival estimates reflect the average prognosis for a given cancer type, but data on cancer survival is scarce in Korea. Data from the KCCR reports an overall 5-year relative survival 
    across age, stage at diagnosis and histology in Korea. Five-year relative survival is highest for localized disease (91.1%) and lowest for distant stage cancers (25.8%) and remains consistent across age groups. With regard to age at the diagnosis, 5-year relative survival is highest in women aged 20–64 (> 90.0% for localized stage, > 70.0% for regional stage and > 30.0% for distant stage), and lowest in women aged 75 and older (63.2% for localized stage, 48.6% for regional stage and 9.4% for distant stage). In addition, 5-year relative survival is higher in SCC than in ADC regardless of stage at diagnosis [26,29].